Hormone and growth factor phosphoglycan mimetics from mycobacterium vaccae

PCT No. PCT/GB96/00669 Sec. 371 Date Feb. 2, 1998 Sec. 102(e) Date Feb. 2, 1998 PCT Filed Mar. 20, 1996 PCT Pub. No. WO96/29425 PCT Pub. Date Sep. 26, 1996A hormone or growth factor mimetic second messenger is derived from a microorganism of the genus Mycobacterium, suitably M. vaccae. The mimetic s...

Full description

Saved in:
Bibliographic Details
Main Authors THOMAS WILLIAM RADEMACHER, GRAHAM ARTHUR WILLIAM ROOK, HUGO NORBERTO CARO
Format Patent
LanguageEnglish
Published 08.10.1996
Edition6
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
DERIVATIVES THEREOF
ENZYMOLOGY
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
NUCLEIC ACIDS
NUCLEOSIDES
NUCLEOTIDES
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROCESSES USING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
SUGARS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:PCT No. PCT/GB96/00669 Sec. 371 Date Feb. 2, 1998 Sec. 102(e) Date Feb. 2, 1998 PCT Filed Mar. 20, 1996 PCT Pub. No. WO96/29425 PCT Pub. Date Sep. 26, 1996A hormone or growth factor mimetic second messenger is derived from a microorganism of the genus Mycobacterium, suitably M. vaccae. The mimetic second messenger may mimic the action of insulin, ACTH, NGF, EGF, FGF, TGF beta or HGF. Further, methods of treating type I or type II diabetes mellitus, polycystic ovary syndrome, central nervous system damage, hepatic damage, alcohol abuse, drug sensitivity, tissue damage, adrenal atrophy, etc., are also disclosed. The methods are carried out by administering the mimetic second messenger to a patient in need thereof.
Bibliography:Application Number: AU19960051164